Vanda Pharmaceuticals Inc.
VNDANasdaqCIK 1347178HealthcareFiscal year ends Dec 31
Reports and events: 361 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2908:00 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001347178-26-000002 |
| 2026-10-2816:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-067886 |
| 2026-08-0607:39 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-053855 |
| 2026-08-0516:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053308 |
| 2026-06-0516:38 ET | 8-K | 5.07 Shareholder vote results | 0001628280-26-041298 |
| 2026-05-0707:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-031667 |
| 2026-05-0616:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031241 |
| 2026-04-2316:48 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001628280-26-026893 |
| 2026-04-2217:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-026642 |
| 2026-04-0216:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-26-023222 |
| 2026-03-1016:47 ET | 8-K | 7.01 Regulation FD disclosure | 0001628280-26-016516 |
| 2026-02-2307:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-010376 |
| 2026-02-1916:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-009805 |
| 2026-02-1207:04 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-007460 |
| 2026-02-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-007256 |
| 2026-01-0807:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-001273 |
| 2025-12-3118:45 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-059155 |
| 2025-12-0416:39 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-055393 |
| 2025-11-2807:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-054225 |
| 2025-10-3007:23 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-047317 |
| 2025-10-2916:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-047112 |
| 2025-10-0117:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-043489 |
| 2025-07-3108:57 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001628280-25-036861 |
| 2025-07-3107:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-036843 |
| 2025-06-0516:32 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-029678 |
| 2025-05-0807:06 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-023448 |
| 2025-05-0716:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-023154 |
| 2025-04-2516:31 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0001628280-25-019987 |
| 2025-03-1709:15 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-25-055287 |
| 2025-02-2016:46 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-030780 |
| 2025-02-1416:32 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-005761 |
| 2025-02-1316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-005406 |
| 2025-01-2708:22 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-25-012740 |
| 2024-11-0707:07 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-045970 |
| 2024-11-0616:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-045724 |
| 2024-10-1508:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-237220 |
| 2024-10-0317:00 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-232306 |
| 2024-09-1908:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-221784 |
| 2024-08-0807:29 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001193125-24-196481 |
| 2024-08-0107:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-033866 |
| 2024-07-3116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-033743 |
| 2024-06-2016:59 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-164545 |
| 2024-06-1316:38 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-160755 |
| 2024-06-0616:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-156117 |
| 2024-05-2416:49 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-025254 |
| 2024-05-2416:31 ET | 8-K/A | 5.07 Shareholder vote results | 0001628280-24-025241 |
| 2024-05-2017:26 ET | 8-K | 5.07 Shareholder vote results | 0001628280-24-024405 |
| 2024-05-0907:07 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-021952 |
| 2024-05-0816:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-021658 |
| 2024-05-0716:51 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-133252 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.